GlassScriptPhysician profile
Jon P Cooney
NPI 1033287313
$20,764.59
in general payments reported to CMS, 2019-2025
21 companies · $3,222 in 2025
The $3,222 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,235 · 2020: $2,801 · 2021: $3,343 · 2022: $2,970 · 2023: $2,465 · 2024: $2,728 · 2025: $3,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,403 · Education: $12.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,402.57 |
| Education | $12.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $3,146.37 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $2,988.86 | 2019-2022 | |
| Alkermes, INC. | $2,368.01 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $2,254.09 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,769.99 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,602.28 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,402.15 | 2019-2025 | Rexulti |
| Allergan, INC. | $1,149.92 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $948.11 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $515.55 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $417.58 | 2022-2024 | Perseris |
| Avanir Pharmaceuticals, INC. | $416.65 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $391.64 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $360.49 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $275.42 | 2024-2025 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $246.40 | 2019-2025 | Austedo Xr, Uzedy |
| Biogen, INC. | $181.29 | 2020-2022 | |
| Eisai INC. | $165.33 | 2020-2021 | |
| Amarin Pharma, INC. | $124.68 | 2019 | |
| Acadia Pharmaceuticals INC | $24.27 | 2024 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Cooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.